SEC Filing Summary: Aadi Bioscience, Inc. (AADI)
Business Context and Reporting Period
This Form 8-K was filed by Aadi Bioscience, Inc. on August 9, 2023. The report serves to announce the Company's financial results for the quarter ended June 30, 2023. The filing incorporates a press release (Exhibit 99.1) by reference. Note: The request metadata referenced "Whitehawk Therapeutics, Inc.", but the filing text explicitly identifies the registrant as "Aadi Bioscience, Inc."
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the attached press release (Exhibit 99.1), which is incorporated by reference but not included in the provided text.
Material Changes
The filing text does not provide specific details regarding material changes versus the prior comparable period. It only confirms the issuance of results for the quarter ended June 30, 2023.
Guidance, Outlook, and Risks
The filing text does not include specific guidance, outlook, management commentary, risks, contingencies, or unusual items. The document states that the information furnished in Item 2.02 and Item 9.01 shall not be deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) in the attached Exhibit 99.1 press release, as they are not present in the 8-K text.
- Confirm the identity of the registrant as Aadi Bioscience, Inc. (AADI), distinct from Whitehawk Therapeutics mentioned in the request metadata.
- Review the full press release for any forward-looking statements or operational updates not summarized in this current report.
- Note the signatory is Scott Giacobello, serving as Interim Chief Executive Officer, President, and Chief Financial Officer.